Citius Pharmaceuticals (CTXR) Net Income (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Net Income came in at -$28.1 million in Q1 2026, down 144.19% YoY from $63.6 million in Q1 2025, and down 199.23% on a QoQ basis from -$9.4 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Net Income (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Net Income data on file, last reported at -$28.1 million in Q1 2026.
- Quarterly Net Income fell 144.19% year-over-year to -$28.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$55.5 million (down 27.64% YoY) and the FY2025 annual result came in at -$39.7 million, down 0.8% from the prior year.
- Net Income declined to -$28.1 million in Q1 2026, from -$9.4 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$3.6 million in Q4 2022 to a low of -$28.1 million in Q1 2026.
- A 5-year average of -$10.2 million and a median of -$9.2 million in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income soared 61.05% — and 2023, when it plunged 156.88%.
- Tracing CTXR's Net Income over 5 years: stood at -$3.6 million in 2022, then sank by 156.88% to -$9.2 million in 2023, then slipped by 11.38% to -$10.3 million in 2024, then grew by 8.63% to -$9.4 million in 2025, then slumped by 199.23% to -$28.1 million in 2026.
- The last three Net Income figures came in at -$28.1 million (Q1 2026), -$9.4 million (Q4 2025), and -$8.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | -11.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.11 Mn |
| Dec 31, 2025 | -9.39 Mn |
| Sep 30, 2025 | -8.74 Mn |
| Jun 30, 2025 | -9.20 Mn |
| Mar 31, 2025 | -11.51 Mn |
| Dec 31, 2024 | -10.28 Mn |
| Sep 30, 2024 | -11.08 Mn |
| Jun 30, 2024 | -10.57 Mn |
| Mar 31, 2024 | -8.54 Mn |
| Dec 31, 2023 | -9.23 Mn |
| Sep 30, 2023 | -9.94 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -10.53 Mn |
| Dec 31, 2022 | -3.59 Mn |
| Sep 30, 2022 | -7.41 Mn |
| Jun 30, 2022 | -8.86 Mn |
| Mar 31, 2022 | -7.56 Mn |
| Dec 31, 2021 | -9.23 Mn |
| Sep 30, 2021 | -5.13 Mn |
| Jun 30, 2021 | -15.01 Mn |